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ABSTRACT:  We have already shown that IL-10 plays an important role in immunosuppression and meta-
static dissemination in the rat B-cell lymphoma L-TACB model. It was suggested that the up-regulation of IL-
10 production and IL-10 receptor (IL-10R) expression would be part of the transition from primary tumor to
metastatic phenotype and that IL-10, besides its immunosuppressive activity, may act as a growth factor for
metastatic L-TACB cells. The treatment of L-TACB-bearing rats with a single low-dose cyclophosphamide
decreased IL-10 production, reverted immunosuppression and induced the immunologic rejection of tumor
metastasis without any effect on primary tumor growth. Our current aim was to investigate the effects of
cyclophosphamide on the expression of IL-10 and IL-10R on primary and metastatic L-TACB cells. Consid-
ering that cyclophosphamide is a prodrug, we used mafosfamide, a compound that yields in vitro the same
active metabolites as cyclophosphamide does in vivo. Mafosfamide induced down-regulation of IL-10 pro-
duction and IL-10R expression on metastatic cells and, concomitantly, inhibited metastatic cell proliferation.
We suggest that mafosfamide would inhibit the regulatory loop mediated by the IL-10/IL-10R system and, as
a consequence, metastatic cell proliferation. These results may have a considerable impact on the design of
new therapies for metastatic lymphomas.
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Introduction
During tumor progression, cancer cells change
(enhance or decrease) the expression of several growth
factors, cytokines, and their specific receptors, as well
as other soluble factors or cell membrane receptors, in
order to grow autonomously and to acquire compe-
tence to metastasis (Pals et al., 2007). Interleukin-10
(IL-10) and its receptor (IL-10R) have been implicated
in progression and metastasis of different tumor types,
including lymphoma. It was shown that the molecular
signature of mantle cell lymphoma (MCL), a non-
Hodgkin lymphoma, included overexpression of IL-
10R, and that IL-10 was able to sustain tumor cell sur-
vival and proliferation (Visser et al., 2000). On the
other hand, overproduction of IL-10 is strongly asso-
ciated with the immunosuppression frequently ob-
served in tumor-bearing hosts and it could be respon-
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sible for the tumor escape from immune rejection
(Salazar-Onfray et al., 2007).
We have proposed that the IL-10/IL10R system
represents a promising therapeutic target for malig-
nant lymphoma (Croci et al., 2007). In our current ex-
periments we used the rat B-cell lymphoma L-TACB
model, in which IL-10 appears to play a pivotal role in
immunosuppression and metastatic dissemination
(Rico et al., 2005), and its inhibition or activity modu-
lation constitutes an important therapeutic option
(Matar et al., 2002). Our previous results in this lym-
phoma model showed a differential effect of cyclophos-
phamide on primary tumor or metastasis growth: a
single low-dose cyclophosphamide inhibited metasta-
sis development without any effect on primary tumor
growth (Matar et al., 1995). This antimetastatic action
of cyclophosphamide was mediated by immunomodu-
lation since this effect could be adoptively transferred
by immune cells of cyclophosphamide-treated tumor-
bearing rats and the same treatment did not induce any
effect in immunodeficient nude mice (Matar et al.,
1998). We showed that IL-10 was the main factor re-
sponsible for the induction and development of im-
munosuppression in L-TACB-bearing hosts and that
the antimetastatic immunomodulatory effect of cyclo-
phosphamide was mediated by a reduction in IL-10
levels produced by T-lymphocytes (Matar et al., 2000;
Matar et al., 2001). In fact, cyclophosphamide induced
a Th2/Th1 switch and increased the proliferation rate
of spleen cells (Matar et al., 2002). Also, we have
shown that L-TACB cells from metastatic nodes pro-
duced high amounts of IL-10 and expressed higher IL-
10 receptor (IL-10R) levels than L-TACB cells from
primary tumors, which did not produce IL-10 at all
(Rico et al., 2005). Also, the addition of IL-10 in vitro
induced an increase in proliferation rate only on meta-
static cells (Matar et al., 2002). It was suggested that
the up-regulation of IL-10 production and IL-10R ex-
pression would be part of the transition from primary
tumor to metastatic phenotype and that IL-10, besides
its immunosuppressive activity, may act as a growth
factor for metastatic L-TACB cells. Altogether, these
results suggested that, in addition to its immunomodu-
latory activity, cyclophosphamide may also be able to
regulate the secretion and/or activity of IL-10 produced
by metastatic cells.
Thus, our current aim was to investigate the in
vitro effects of active metabolites of cyclophosphamide
on the expression of IL-10 and its specific receptor
IL-10R on both primary tumor and metastatic L-TACB
cells.
Materials and Methods
Drugs
Considering that cyclophosphamide is a prodrug,
we used mafosfamide (Baxter Oncology GmbH, Ger-
many), a compound that yields in vitro the same ac-
tive metabolites as cyclophosphamide does in vivo
(Niemeyer et al., 1984). Solutions of 2.5, 5, 10 and 20
μM mafosfamide were prepared in RPMI-1640 cul-
ture medium (Gibco BRL, Gaithersburg, MD, USA).
Tumor
L-TACB is a poorly differentiated B-cell lym-
phoma that arose spontaneously in an inbred e rat
(Calderari et al., 1991). It is maintained by serial sub-
cutaneous grafting by trocar of 1 mm3 tumor fragments
(approximately 106 cells) in syngeneic rats. When L-
TACB is injected s.c., metastases occur exclusively in
regional (axillary or inguinal) homolateral or contralat-
eral lymph nodes in 20–30% of the animals.
Preparation of tumor single-cell suspensions
To obtain single-cell suspensions from primary tu-
mor and metastasis, e rats were implanted subcutane-
ously with L-TACB and 21 days later primary tumors
and lymph node metastases were excised and cell sus-
pensions were obtained by mechanical disruption in
RPMI-1640 culture medium. At this time of tumor pro-
gression, hematoxylin–eosin staining showed that nor-
mal lymphoid tissue in an organized form was com-
pletely replaced by tumor tissue in lymph nodes, and
that the only non lymphoid cells appearing could be
assigned to nervous tissue and blood vessels (data not
shown).
Cell proliferation
Primary and metastatic L-TACB cells were incu-
bated at 1x104 per well in 100 μl RPMI-1640 culture
medium with 10% fetal calf serum (FCS) (Natocor,
Córdoba, Argentina) containing 0, 2.5, 5, 10 or 20 μM
mafosfamide, at 37ºC and 5% CO
2
 for 48 h in 96-well
plates. Cell proliferation was determined by the colo-
rimetric WST-1 assay (Roche Diagnostics, Mannheim,
Germany) following manufacturer instructions. Deter-
minations were done in quadruplicate.
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Figure 1. Effect of mafosfamide on cell proliferation, IL-10 production and IL-10R expression of primary
tumor cells (1A,1C,1E, respectively) and metastatic cells (1B,1D,1F) of B-cell lymphoma L-TACB. ANOVA:
(B) mafosfamide 0 μM vs 5, 10 or 20 μM, P<0.05; (D) mafosfamide 0 μM vs 2.5, 5, 10 or 20 μM, P<0.05;
(F) mafosfamide 0 μM vs 5, 10 or 20 μM, P<0.05.
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Quantification of IL-10
The concentration of IL-10 was measured in con-
ditioned media from primary tumor or metastatic L-
TACB cells by a sandwich ELISA assay.  Five x 105
cells of each cell type suspended in 5 ml of RPMI-1640
culture medium supplemented with 10% FCS and
mafosfamide (0-20μM) were seeded in 25 cm2 culture
flasks. After 48 h incubation at 37ºC and 5% CO
2
, cul-
ture supernatants were collected and centrifuged. The
cell-free conditioned media were aliquoted and stored
at -20ºC until used. The ELISA sandwich technique,
that uses two different antibodies against different
epitopes of IL-10, was carried out according to the in-
structions provided in the kit (OptEIATM Rat IL-10 Set;
Pharmingen, San Diego, CA, USA).
Expression of IL-10 receptor (IL-10R)
The effect of mafosfamide on IL-10R expression
on primary tumor or metastatic cells was determined
by CELISA (cellular ELISA) assay. Cells were pre-in-
cubated with 0, 2.5, 5, 10 or 20 μM mafosfamide dur-
ing 48 h and then fixed at 5 x 105 cells/well onto 96
wells microtiter plates with 0.5% formaldehyde-buffer
for 18 h at 37ºC. Then, recombinant IL-10 (rIL-l0) at a
saturating concentration (5000 pg/ml) was added. The
plates were incubated 2 h at room temperature, washed,
blocked and then incubated for 1 h with anti-IL-l0-bi-
otin/streptavidin-peroxidase conjugate. After the addi-
tion of tetramethylbenzidine and H
2
O
2
 and 30 min in-
cubation at room temperature in the dark, the reaction
was stopped with H
2
SO
4
. The optical density was deter-
mined at 450-570 nm. All samples were assayed in qua-
druplicate.
Statistical analysis
ANOVA was performed using GraphPad Prism®
version 3.03 (GraphPad Software, San Diego, CA,
USA). Differences between groups were considered sig-
nificant when P < 0.05.
Results
Effect of mafosfamide on primary and metastatic L-
TACB cell proliferation
Mafosfamide did not show any effect on primary
tumor cells proliferation (Fig. 1A). In contrast, meta-
static L-TACB cells were sensitive to the antiprolifera-
tive effect of mafosfamide in a dose-dependent man-
ner, from 5 to 20 μM, when compared to cells incu-
bated without mafosfamide (P<0.05) (Fig. 1B).
Effect of mafosfamide on IL-10 production
Quantification of IL-10 showed non-detectable lev-
els in conditioned media from primary tumor cells (Fig.
1C), while the IL-10 levels in conditioned media from
metastatic cells were higher in control cells than in cells
treated with different doses of mafosfamide (P<0.05)
(Fig. 1D). Considering that mafosfamide exerts a dose-
dependent antiproliferative effect on metastatic cells
(Fig. 1B), IL-10 levels were normalized to cell number
for each mafosfamide concentration. In this condition,
we also observed a mafosfamide-induced dose-depen-
dent reduction of IL-10/cell (data not shown).
Effect of mafosfamide on IL-10R expression
The results showed that primary tumor cells ex-
pressed low levels of IL-10R, which were not signifi-
cantly modified by either dose of mafosfamide (Fig.
1E). On the contrary, metastatic L-TACB cells expressed
higher levels of IL-10R with respect to primary tumor
cells (P<0.05). Moreover, incubation with mafosfamide
decreased IL-10R expression on metastatic L-TACB
cells at doses of 5 to 20 μM (P<0.05) (Fig. 1F).
Discussion
In this rat lymphoma model, as well as in human
lymphomas, IL-10 plays a central role in the inhibition
of the antitumor immune response as well as a growth
factor for metastasis. Nowadays, high levels of IL-10
are considered as significant unfavorable prognostic
factor and an International Prognostic Score-indepen-
dent risk factor for treatment failure in advanced
Hodgkin lymphoma (Matar et al., 2001; Rautert et al.,
2008). We have shown that the treatment of lymphoma-
bearing rats with a single low-dose cyclophosphamide
inhibited metastasis development, and that this effect
was mediated by cyclophosphamide-induced immuno-
modulation, mainly through a reduction in IL-10 levels
(Matar et al., 1998; 2000). We have also indicated that
IL-10 may act as a growth factor for metastatic tumor
cells in addition to its immunosuppressive activity (Rico
et al., 2005). Similar results were obtained in leukemic
mantle cell lymphoma (Visser et al., 2000), B16 mouse-
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melanoma model (García-Hernández et al., 2002), and
freshly resected primary tumor and metastases from
melanoma patients (Yue et al., 1997). As far as we know,
we demonstrated here a novel effect of mafosfamide on
the expression of IL-10 and its specific receptor on lym-
phoma cells. We observed that mafosfamide, a deriva-
tive of 4-hydroxycyclophosphamide, induced down-
regulation of IL-10 production and IL-10R expression
on metastatic tumor cells and, concomitantly, inhib-
ited metastatic cell proliferation. Taking into account
that IL-10 induces in vitro metastatic cell prolifera-
tion (Matar et al., 2002), and that metastatic cells si-
multaneously express IL-10R and produce IL-10, an
autocrine and/or paracrine loop would take place, thus
stimulating, either directly or indirectly, metastatic cell
proliferation. We suggest that mafosfamide would in-
hibit the regulatory loop mediated by the IL-10/IL-
10R system and, as a consequence, it would inhibit
metastatic cell proliferation. Considering that
mafosfamide yields the same active metabolites as
cyclophosphamide in equimolar concentrations, it can
be hypothesized that cyclophosphamide in vivo would
produce a similar effect than mafosfamide in vitro.
Then, the effects of IL-10 we have previously observed
in L-TACB-bearing rats, namely, immunosuppression
and induction of metastatic cells proliferation, could
have been abrogated when animals were treated with
antimetastatic low doses of cyclophosphamide. These
results may have considerable impact on development
of new therapies for metastatic lymphomas in view that
a single low-dose of cyclophosphamide, a treatment
devoid of toxicity, would act inhibiting at least two
mechanisms contributing to malignant growth and pro-
gression: escape to immune rejection and autonomous
growth of metastatic tumor cells.
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